ENTX EBITDA | ENTERA BIO LTD.

ENTERA BIO LTD. (ENTX) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$4.56M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$3.54M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$3.26M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$2.67M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$4.56M	(m)	(m)	(m)	$3.00K*	-$3.46M*	(m)	$3.20M	$124.00K	(m)
2026-03-31	Reported	(m)	-$3.54M	(m)	(m)	(m)	$0.00	-$3.09M	(m)	$2.25M	$128.00K	(m)
2025-09-30	Reported	(m)	-$3.26M	(m)	(m)	(m)	$43.00K*	-$2.50M*	(m)	$1.64M	$122.00K	(m)
2025-06-30	Reported	(m)	-$2.67M	(m)	(m)	(m)	$29.00K*	-$1.63M*	(m)	$1.52M	$103.00K	(m)
2025-03-31	Reported	(m)	-$2.56M	(m)	(m)	(m)	$8.00K	-$1.40M	(m)	$1.12M	$123.00K	(m)
2024-09-30	Reported	(m)	-$3.02M	(m)	(m)	(m)	$0.00*	-$2.15M*	(m)	$1.48M	$62.00K	$0.00
2024-06-30	Reported	(m)	-$2.17M	(m)	(m)	(m)	$0.00*	-$1.33M*	(m)	$1.09M	$134.00K	(m)
2024-03-31	Reported	(m)	-$2.06M	(m)	(m)	(m)	$0.00	-$1.86M	(m)	$735.00K	(m)	(m)
2023-09-30	Reported	(m)	-$2.39M	(m)	(m)	(m)	$0.00*	-$1.52M*	(m)	$1.37M	(m)	$29.00K
2023-06-30	Reported	(m)	-$2.33M	(m)	(m)	(m)	$1.00K*	-$1.56M*	(m)	$1.21M	(m)	$0.00
2023-03-31	Reported	(m)	-$2.21M	(m)	(m)	(m)	$11.00K	-$1.61M	(m)	$931.00K	(m)	$0.00
2022-09-30	Reported	(m)	-$2.87M	(m)	(m)	(m)	$2.00K*	-$2.87M*	(m)	$1.41M	(m)	$194.00K
2022-06-30	Reported	(m)	-$3.25M	(m)	(m)	(m)	$19.00K*	-$2.83M*	(m)	$1.39M	(m)	-$4.00K
2022-03-31	Reported	(m)	-$3.83M	(m)	(m)	(m)	$23.00K	-$4.79M	(m)	$1.69M	(m)	-$7.00K
2021-09-30	Reported	(m)	-$3.22M	(m)	(m)	(m)	$7.00K*	-$2.11M*	(m)	$1.77M	(m)	-$13.00K
2021-06-30	Reported	(m)	-$2.57M	(m)	(m)	(m)	$0.00*	-$2.12M*	(m)	$1.23M	(m)	-$17.00K
2021-03-31	Reported	(m)	-$2.34M	(m)	(m)	(m)	$0.00	-$2.32M	(m)	$1.12M	(m)	-$14.00K

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$11.53M	(m)	(m)	(m)	$107.00K	-$7.37M	(m)	$6.00M	$398.00K	$0.00
2024-12-31	Reported	(m)	-$9.59M	(m)	(m)	(m)	$3.00K	-$6.82M	(m)	$4.50M	$340.00K	$14.00K
2023-12-31	Reported	(m)	-$8.89M	(m)	(m)	(m)	$17.00K	-$7.31M	(m)	$4.51M	(m)	$29.00K
2022-12-31	Reported	(m)	-$13.02M	(m)	(m)	(m)	$47.00K	-$12.50M	(m)	$5.85M	(m)	$137.00K
2021-12-31	Reported	(m)	-$12.22M	(m)	(m)	(m)	$17.00K	-$9.06M	(m)	$6.77M	(m)	-$59.00K
2020-12-31	Reported	(m)	-$11.17M	(m)	(m)	(m)	$53.00K	-$10.56M	(m)	$6.38M	(m)	$20.00K

Stock Name	Country	Market Cap	PE Ratio
REGENXBIO Inc. (RGNX)	United States	$0.477B	-3.30
Tectonic Therapeutic, Inc. (TECX)	United States	$0.469B	-7.68
Autolus Therapeutics plc (AUTL)		$0.506B	-1.52
Eikon Therapeutics, Inc. (EIKN)	United States	$0.446B
Kyverna Therapeutics, Inc. (KYTX)	United States	$0.434B	-3.60
Editas Medicine, Inc. (EDIT)	United States	$0.424B	-4.29
Prime Medicine, Inc. (PRME)	United States	$0.557B	-3.54
Scribe Therapeutics, Inc. (SCTX)	United States	$0.410B
Zura Bio Ltd (ZURA)		$0.398B	-6.56
Allogene Therapeutics, Inc. (ALLO)	United States	$0.574B	-4.33